From GlobeNewswire: 2024-04-09 16:05:00

ImmuCell Corporation (Nasdaq: ICCC) has reported preliminary, unaudited total sales results for the first quarter of 2024, showing a significant increase in sales compared to the first quarter of 2023 and exceeding previous quarterly records. Total sales for the three-month period ended March 31, 2024, were $7.3 million, a 111% increase from the same period in 2023. The company also announced plans to host a conference call on May 10, 2024, to discuss these results and provide further information. ImmuCell continues to focus on increasing production to meet demand and obtaining FDA approval for Re-Tain®.

Total sales for the twelve-month period ended March 31, 2024, were $21.3 million, a 33% increase from the previous year. The backlog of orders as of March 31, 2024, was worth approximately $9.1 million, a slight decrease from the end of 2023 but a significant increase from the end of 2022. ImmuCell President and CEO Michael F. Brigham expressed optimism about the company’s performance and the ongoing efforts to achieve FDA approval for Re-Tain®. Interested parties can access a conference call on May 10, 2024, for more details on the unaudited financial results.



Read more at GlobeNewswire: ImmuCell Announces Preliminary, Unaudited Sales Results for